Posted in | News

Toyo Engineering + Construction to Build Glycos Biotechnologies’ Asian Facility

Glycos Biotechnologies, (GlycosBio), a global biochemical company marketing valuable and renewable specialty chemicals, declared that it has selected Toyo Engineering & Construction (Toyo Malaysia) to offer procurement, engineering and construction (EPC) services for its Johor, Malaysia-based industrial biochemical production facility.

GlycosBio’s commercial facility will be built inside a biotechnology park, Bio-XCell. GlycosBio’s plant building will be done by the second quarter of 2013.

GlycosBio’s President, Walt Burnap, teamed together with executives from Toyo and Bio-XCell like Toji Kawakami, Managing Director Toyo Malaysia and Rizatuddin Ramli, CEO of Bio-XCell at an event held on December 6th in Malaysia.

The facility will be built in a number of phases with 30,000 Mt production rate capacity per year expected to be attained by 2014 with a subsequent increase up to 90,000 Mt. Isoprene, used in the synthetic rubber market is the targeted biochemical for GlycosBio’s plant. The company will initially be focused on validating its capability for industrial ethanol production from crude glycerin and further interested in using different feedstocks comprising fatty acids. GlycosBio’s complete production facility attributes to isoprene production from cheap, renewable feedstocks that can be obtained easily in Malaysia.

GlycosBio, through its affiliation with Bio-XCell, first revealed its interest in 2010 to expand to Malaysia and will be the first US-based company at the industrial park in Johor, Malaysia. GlycosBio is a recipient of BioNexus status in 2011, qualified by the Malaysian Government to support the advancement of biotechnology.

Source: http://www.glycosbio.com/

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Scanlon, Joel. (2019, February 22). Toyo Engineering + Construction to Build Glycos Biotechnologies’ Asian Facility. AZoBuild. Retrieved on November 25, 2024 from https://www.azobuild.com/news.aspx?newsID=14697.

  • MLA

    Scanlon, Joel. "Toyo Engineering + Construction to Build Glycos Biotechnologies’ Asian Facility". AZoBuild. 25 November 2024. <https://www.azobuild.com/news.aspx?newsID=14697>.

  • Chicago

    Scanlon, Joel. "Toyo Engineering + Construction to Build Glycos Biotechnologies’ Asian Facility". AZoBuild. https://www.azobuild.com/news.aspx?newsID=14697. (accessed November 25, 2024).

  • Harvard

    Scanlon, Joel. 2019. Toyo Engineering + Construction to Build Glycos Biotechnologies’ Asian Facility. AZoBuild, viewed 25 November 2024, https://www.azobuild.com/news.aspx?newsID=14697.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.